on CROSSJECT (EPA:ALCJ)
Crossject publishes information on its share capital
On November 6, 2026, CROSSJECT announced its share capital figures. Specializing in the development of pharmaceutical solutions for emergencies, CROSSJECT uses its ZENEO® technology, a needle-free auto-injector. As of August 31, 2026, the company's share capital consisted of 60,353,167 shares.
The total number of theoretical voting rights was 72,043,454, while the number of exercisable voting rights was 71,991,765. This difference is due to 51,689 shares deprived of voting rights, including shares held by the company and those under the liquidity contract.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CROSSJECT news